Opinion
Video
Author(s):
Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Intervention to increase fluid intake does not reduce recurrent stones
Physical function and frailty measures offer distinct insights in patients with bladder cancer
FDA to host advisory committee meeting on UGN-102 for NMIBC
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC